vimarsana.com
Home
Live Updates
Extended Follow-up of Microbiome Therapeutic SER-109 Through
Extended Follow-up of Microbiome Therapeutic SER-109 Through
Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial | Gastroenterology | JAMA
This study examines adverse events and durability of response of SER-109, an investigational microbiome therapeutic comprised of purified Firmicutes spores, com
Related Keywords
Cambridge ,
Cambridgeshire ,
United Kingdom ,
Georgia ,
United States ,
Springfield ,
Barbarah Mcgovern ,
Leonard Meron Biosciences ,
Kristin Walter ,
Jodyw Zylke ,
Jeffrey Williams ,
Steven Omarro ,
Aasim Sheikh ,
Doria Grimard ,
Janssen Research ,
Regeneron Pharmaceuticals ,
Alkermes ,
Sciences Inc ,
Genentech Inc ,
Genesis Research ,
Astrazeneca ,
Md Summit Clinical Research ,
Charlson Comorbidity Index ,
Deputy Editor ,
Seres Therapeutics ,
Interest Disclosures ,
Finch Therapeutics ,
Vedanta Biosciences ,
Diasorin Molecular ,
Summit Therapeutics ,
Sharing Statement ,
Summit Clinical Research ,
Steveno Marro ,
Springfield Clinic ,
Complexe Hospitalier De La Sagamie ,
Gastrointestinal Specialists ,